ResearcherAbramson Cancer CenterActive in the last 2 years
Timothy J. Brown
Matched on ORCID iD 0000-0002-4843-4639; OpenAlex author ID A5009574042. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 3 papers
Papers 6
- Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
- Proper Phenotyping of Pancreatic Cancer in Database Research. First author DOI 10.1001/jamaoncol.2026.2609↗
- Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey. Co-author DOI 10.1002/cncr.70446↗
- The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
- Advancements in Systemic Therapy for Pancreatic Cancer. Co-author DOI 10.1200/edbk_397082↗
- PARP Inhibitors in Pancreatic Cancer. Co-author DOI 10.1097/ppo.0000000000000554↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kim A. Reiss · 4 shared papers, 2021–2026 · strength 0.98
- Paper Advancements in Systemic Therapy for Pancreatic Cancer. DOI 10.1200/edbk_397082↗
- Paper PARP Inhibitors in Pancreatic Cancer. DOI 10.1097/ppo.0000000000000554↗
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Mark H. O’Hara · 3 shared papers, 2023–2026 · strength 0.70
- Paper Advancements in Systemic Therapy for Pancreatic Cancer. DOI 10.1200/edbk_397082↗
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, B… DOI 10.1158/1078-0432.ccr-23-1467↗
- Jeffrey W. Shevach · 1 shared paper, 2026 · strength 0.63
- Susan M. Domchek · 2 shared papers, 2023–2026 · strength 0.39
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, B… DOI 10.1158/1078-0432.ccr-23-1467↗
- Katherine L. Nathanson · 2 shared papers, 2023–2026 · strength 0.39
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, B… DOI 10.1158/1078-0432.ccr-23-1467↗
- Naomi H. Fei · 1 shared paper, 2026 · strength 0.27
- Udhayvir Singh Grewal · 1 shared paper, 2026 · strength 0.27
- Chandrikha Chandrasekharan · 1 shared paper, 2026 · strength 0.27
- Kawther Abdilleh · 1 shared paper, 2026 · strength 0.27
- Zain M. Hannan · 1 shared paper, 2026 · strength 0.24
- Robert H. Vonderheide · 1 shared paper, 2026 · strength 0.24
- Thomas Benjamin Karasic · 1 shared paper, 2023 · strength 0.16
- Jacob Edward Till · 1 shared paper, 2023 · strength 0.16
- Erica L. Carpenter · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.